Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ScanCell’s DNA Plasmid-Cancer Vaccine Shows Promise In Melanoma

This article was originally published in The Pink Sheet Daily

Executive Summary

ScanCell Holdings’ potential DNA cancer vaccine, which is administered via an electrical field-driven device, shows preliminary evidence of efficacy in late-stage melanoma patients.

You may also be interested in...



In Europe, A Public-Private Effort Could Shed Light On The Tricky Business Of Cancer Vaccines

With EU cash in hand, the GAPVAC consortium aims to develop tailor-made vaccines for patients with the rare but aggressive brain cancer, glioblastoma. The vaccines will be unique to each individual, but hopefully with increased efficacy compared with other therapies, thereby justifying the likely higher cost and complexity of treatment.

New EU-Funded Consortium Aims To Develop Targeted Cancer Vaccines

A clinical trial is expected to start in the U.S. and Europe in 2014 of an individualized approach to developing a cancer vaccine for glioblastoma patients.

Glaxo Confident In Output From Its Revamped R&D Engine

Britain’s biggest drug maker updated the investment community on its pipeline prospects Dec. 3, outlining a timescale of three pipeline “waves” that will include pivotal clinical trial results on up to 14 medicines in the next two years.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073701

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel